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Abstract
Background: The taxanes paclitaxel and docetaxel have traditionally been used in high doses
every third week in the treatment of cancer. Lately there has been a trend towards giving weekly
low doses to improve the therapeutic index. This article describes the development of high
performance liquid chromatographic (HPLC) methods suitable for monitoring taxane levels in
patients, focusing on patients receiving low-dose therapy.
Methods: Paclitaxel and docetaxel were extracted from human plasma by solid phase extraction,
and detected by absorbance at 227 nm after separation by reversed phase high performance liquid
chromatography. The methods were validated and their performance were tested using samples
from patients receiving paclitaxel or docetaxel.
Results: The limits of quantitation were 1 nM for docetaxel and 1.2 nM for paclitaxel. For both
compounds linearity was confirmed from the limit of quantitation up to 1000 nM in plasma. The
recoveries ranged between 92% and 118% for docetaxel and between 76% and 104% for paclitaxel.
Accuracy and precision were within international acceptance criteria, that is within ± 15%, except
at the limit of quantitation where values within ± 20% are acceptable. Low-dose patients included
in an on going clinical trial had a median docetaxel concentration of 2.8 nM at 72 hours post
infusion. Patients receiving 100 mg/m2 of paclitaxel had a mean paclitaxel concentration of 21 nM
48 hours after the end of infusion.
Conclusion: We have developed an HPLC method using UV detection capable of quantifying 1
nM of docetaxel in plasma samples. The method should be useful for pharmacokinetic
determinations at all relevant doses of docetaxel. Using a similar methodology paclitaxel can be
quantified down to a concentration of 1.2 nM in plasma with acceptable accuracy and precision. We
further demonstrate that the previously reported negative influence of Cremophor EL on assay
performance may be overcome by degradation of the detergent by incubation with lipase.
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Background
Paclitaxel (figure 1a) was discovered in the early 1970's as
being the active cytotoxic constituent in extracts of the
bark of the yew Taxus Brevifolia. Paclitaxel had a unique
mechanism of action, but the supply was limited and for-
mulation of the compound for clinical use was difficult as
paclitaxel is practically insoluble in water. Docetaxel (fig-
ure 1b), a semisynthetic analog of paclitaxel with higher
aqueous solubility, was constructed from 10-deacetyl bac-
catin III about 10 years later. Several review articles on the
clinical and preclinical pharmacokinetics of paclitaxel and
docetaxel have been published [1-3].
Docetaxel for clinical use is currently formulated as a con-
centrate in polysorbate 80, and about 4 ml of this non-
ionic detergent is infused together with a standard dose
(173 mg) of docetaxel. The plasma concentration of
polysorbate 80 is about 0.1% during the infusion and the
compound is rapidly cleared from plasma [4,5]. This is in
contrast to Cremophor EL, the solvent for paclitaxel,
where about 27 ml is infused together with a standard
dose (303 mg), and the plasma concentration remains
high (above 0.1%) for days due to a low volume of distri-
bution (3 L/m2) and a long half-life (40–80 h) [6-10].
Cremophor EL has been reported to have a negative influ-
ence on the reproducibility of paclitaxel determinations
[11]. No such effects have been reported for polysorbate
80 and docetaxel.
Numerous analytical methods for the taxanes have been
published. Most of them rely on sample preparation by
solid phase extraction followed by separation by HPLC
and detection by absorbance at 225–230 nm. The major-
ity of methods for both paclitaxel and docetaxel are based
on the principles for extraction and separation published
by Willey et al. [12] in 1993, but also methods based on
organic extraction are used [13-15]. Lately, mass spec-
trometry (MS) based methods with simplified sample
preparations and limits of detections in the sub-nanomo-
lar range have appeared [4,16-19]. The improved sensitiv-
ity has given new insight into the pharmacokinetics of the
taxanes [20,21].
The method development presented here was started to
support a dose escalation study with paclitaxel in patients
with ovarian cancer. As we lacked an MS-instrument, the
detection utilized UV absorbance. Later on the develop-
ment of an HPLC method for docetaxel was initiated,
based on the experiments performed with paclitaxel.
We present here a validated reversed phase HPLC method
based on UV detection that has sufficient sensitivity to
perform pharmacokinetic determinations at all relevant
doses of docetaxel. With a similar methodology, paclitaxel
may be quantified down to a concentration of 1.2 nM in
plasma. We also demonstrate that it is possible to elimi-
nate Cremophor EL from plasma samples by degradation
of the detergent with lipase.
Methods
Chemicals and reagents
Docetaxel reference standard (lot 9915420, purity 98.5%)
was initially supplied by Aventis Pharma (Vitry Alforville
research Center, France) but later purchased from ARC
Inc. (St. Louis, MO, USA). Cremophor EL, 14C-paclitaxel
([2-benzoyl ring-UL-14C], 62.9 mCi/mmol in ethyl ace-
tate) and semisynthetic paclitaxel was purchased from
Sigma Chemical Co. (St. Louis, MO, USA). 3H-paclitaxel
(10.5 Ci/mmol in ethanol) and natural non-labelled pacl-
itaxel was purchased from Moravek Biochemicals (Brea,
CA, USA). 2'-methylpaclitaxel (lot 001, purity 95%) was
obtained from Bristol-Meyers Squibb (Syracuse, NY,
USA). Coomassie Brilliant Blue G-250 was purchased as a
concentrate from Bio-Rad Laboratories (Munich, Ger-
many). Lipase from Rhizopus arrhizus (EC 3.1.1.3), 50
kU/ml, was purchased from Roche (Basel, Switzerland).
HPLC grade methanol was from Mallinckrodt Baker B.V.
(Deventer, Holland). Acetonitrile (HPLC grade) and
sequencer grade n-butyl chloride were from Rathburn
(Walkerburn, UK). FluoranFlow scintillation fluid was
from BDH (Poole, UK). Drug-free EDTA plasma was
obtained from healthy donors.
Preparation of standards
Stock solutions of taxane reference standards were made
up in acetonitrile and stored at -70°C. Further dilutions to
make calibration standards in EDTA plasma were per-
formed on the day of use. 3H-paclitaxel was used as inter-
nal standard for the determination of paclitaxel. The
Molecular structure of paclitaxel and docetaxel Figure 1
Molecular structure of paclitaxel and docetaxel. 
Molecular structure of paclitaxel (1a) and docetaxel (1b). 
Dissimilarities are marked in blue (1a) and red (1b).
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received standard was diluted 1:20 in acetonitrile, aliq-
uoted in glass vials and stored at -70°C. Before use these
solutions were further diluted in acetonitrile to a final
concentration of 0.45 nCi/µl, and 20 µl were added to
each 4 ml sample of plasma giving a final paclitaxel con-
centration of 0.2 nM. 14C-paclitaxel was used as a tracer
during the methods development. The received concen-
trate was diluted in ethanol and stored at -70°C in glass
vials.
Instrumentation
All chromatographic equipment was produced by Shi-
madzu Corp. (Tokyo, Japan). The solvent delivery system
consisted of a LC-9A quartenary gradient pump, a DGU-
3A on-line degasser and a CTO-6A column oven and on-
line solvent preheater. Samples were injected with a SIL-
6B autoinjector and detected by a SPD-6AV variable wave-
length UV detector. Data acquisition and integration were
performed by a Class-VP 4.2 computer-based integration
system. Quantitations of 14C-labelled and 3H-labelled
paclitaxel were undertaken using a 1211 RackBeta liquid
scintillation counter from Wallac Oy (Turku, Finland).
Sample processing
The taxanes were extracted from samples of human
plasma using solid phase extraction (SPE). The individual
steps in the sample preparation are tabulated in table 1,
together with the two methods we used as basis for this
method development. SPE were performed using col-
umns containing 100 mg of CN packing material (with or
without endcapping, see table 1) and having a reservoir
capacity of 10 ml (LRC-SPE columns, Varian, Harbor City,
CA, USA).
The activation, sample extraction and the first two washes
were performed by gravity, i.e. no vacuum was used.
Twenty microlitres of internal standard was added to the
plasma samples: for the determination of paclitaxel 3H-
paclitaxel (0.45 nCi/µl), for the determination of
docetaxel 20 µM semisynthetic paclitaxel. The plasma
samples were mixed thoroughly and centrifuged at 2000 g
for 15 minutes. The full volume of sample, leaving only
the pellet was pipetted onto the activated SPE-columns.
After the second wash, vacuum was applied and the col-
umns were washed with hexane and dried by running air
through the columns at full vacuum for 3 minutes. The
taxanes were eluted into 1.1 ml tapered glass vials
(Chromacol 1.1-STVG) with two successive 250 µl aliq-
uots of ethyl acetate. The samples were evaporated to dry-
ness in a vacuum centrifuge and dissolved in 40%
acetonitrile by sonication for 2 minutes in a Branson 1200
ultrasonic waterbath followed by vortex mixing. Ninety
microlitres of sample was injected onto the HPLC system.
HPLC conditions
The paclitaxel samples were separated on a Supelcosil LC-
18 column (4.6 × 150 mm, particle size 3 µm; Supelco
Inc, PA, USA) protected by a 0.5 µm precolumn filter and
a 20 mm LC-18 Supelguard. The mobile phase consisted
of 20 mM potassium phosphate buffer (pH 3.0): ace-
tonitrile (55:45 v/v) delivered at a flow rate of 1 ml/min.
The buffer was made up by pH adjustment of a solution
of phosphoric acid with 10 M potassium hydroxide. The
Table 1: Solid Phase Extraction
Paclitaxel Docetaxel
Author Willey [12] Andersen et al Rosing [24] Andersen et al
Columns 1 ml CN-(?) 100 mg# LRC CN-U 100 mg CN-E 100 mg LRC CN-E 100 mg
Cond 1 2 ml MeOH 10 ml MeOH 1 ml 0.1% TEA in MeCN 10 ml MeOH
Cond 2 2 ml AmAc## 5 ml AmAc 2 ml MeOH 2 ml AmAc
Cond 3 None None 2 ml AmAc None
Load 1 ml 50% plasma* Up to 8 ml 50% plasma* 1.1 ml undiluted plasma 2 ml undiluted plasma
Wash 1 2 ml AmAc 10 ml AmAc 2 ml AmAc 2 ml AmAc
Wash 2 2 ml AmAc/20% MeOH 1 ml AmAc/20% MeOH 1 ml water/20% MeOH 1 ml AmAc/20% MeOH
Wash 3 1 ml hexane 5 ml hexane None 2 ml hexane
Elution 2× 1 ml 0.1% TEA in MeCN 2× 250 µl ethyl acetate 1× 500 µl 0.1% TEA in 
MeCN
2× 250 µl ethyl acetate
Evap Nitrogen gas blowdown Vacuum centrifuge Nitrogen gas blowdown Vacuum centrifuge
Injection volume 100 µl (of 200 µl) in MeOH/
MeCN/AmAc
90 µl (of 100 µl) in 40% 
MeCN
50 µl (of 100 µl) in MeOH/
MeCN/water
90 µl (of 100 µl) in 40% 
MeCN
The taxanes were extracted from samples of human plasma using solid phase extraction. The individual steps in the solid phase extraction are 
shown, together with the two methods we used as basis for this method development.
MeOH = methanol, MeCN = acetonitrile
# Not specified if the columns were endcapped or not.
## AmAc = 10 mM ammonium acetate buffer pH 5.0.
* The plasma samples were mixed with an equal volume of 0.2 M ammonium acetate pH 5.0.BMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
Page 4 of 10
(page number not for citation purposes)
column temperature was maintained at 40°C, and the UV
detector was operated at 227 nm.
The docetaxel samples were separated on a Purospher®
STAR RP-18e column (3.0 × 125 mm, particle size 3 µm;
Merck, Darmstadt, Germany) protected by a 0.5 µm pre-
column filter and a 4 mm guard cartridge. The mobile
phase consisted of 20 mM potassium phosphate buffer
(pH 3.0): acetonitrile (57.5:42.5 v/v) delivered at a flow
rate of 0.8 ml/min. The column temperature was main-
tained at 55°C, and the UV detector was operated at 227
nm.
Determination of Cremophor EL
With some minor modifications, Cremophor EL concen-
trations in plasma were determined by the linearized ver-
sion [8] of the method of Sparreboom et al. [22]. Twenty-
five microlitres of plasma was deproteinized by the addi-
tion of 250 µl acetonitrile in 2 ml micro centrifuge tubes
(Costar 3213) followed by vortex mixing. One ml of n-
butyl chloride was added, and after a brief mixing the
tubes were placed in a sonicating waterbath at 40°C for
10–15 minutes. The organic layer was separated by cen-
trifugation at 26000 g for 5 minutes in a Hermle Z252MK
centrifuge (Maschinenfabrik Berthold Hermle AG, Gos-
heim, Germany), transferred to a clean 2 ml micro centri-
fuge tube, and evaporated to dryness in a vacuum
centrifuge. The residue was reconstituted in 100 µl of 10%
methanol in water (v/v), and duplicate volumes of 40 µl
were transferred to flat bottom 96-well micro titre plates
(Nunc A/S, Roskilde, Denmark). Two hundred and fifty
microlitres of diluted (1:10 in water v/v) Coomassie Bril-
liant Blue concentrate was added to each well, and the
absorbance at 620 and 450 nm were measured with a
1420 Victor multilabel counter (Wallac Oy, Turku, Fin-
land). Cremophor EL concentrations in plasma were cal-
culated from the absorbances as outlined by Brouwer [8].
Validation
The analytical methods were validated regarding linearity,
recovery, accuracy, precision, sensitivity and sample vol-
ume based on the criteria described by Shah et al. [23].
Solid phase extraction, recovery studies
Total recovery was determined by comparing peak areas
of processed samples with peak areas of standards in 40%
acetonitrile injected directly without processing. To facili-
tate the recovery-studies, 14C-paclitaxel was used as tracer,
as samples of flow-through and wash solutions from the
SPE-procedure could not be injected directly onto the
HPLC. Recovery studies of every step in the extraction pro-
cedure of Willey et al. [12] were performed to improve the
sensitivity of the assay.
To determine maximum sample capacity and losses dur-
ing the sample preparation, three samples of 5 ml EDTA-
plasma containing 50 nM 14C-paclitaxel were mixed with
an equal volume of a 200 mM ammonium acetate buffer
pH 5.0 and loaded by gravity onto activated SPE-columns.
Except for the increased sample volume, the SPE-proce-
dure was performed as outlined by Willey et al. [12]. The
flow-through, washes and eluates were collected in frac-
tions, and paclitaxel concentration determined by scintil-
lation counting.
To determine the optimal flow during the extraction, a
total of 18 samples of 4 ml EDTA-plasma containing 500
nM paclitaxel (14C-paclitaxel as tracer) were mixed with
an equal volume of a 200 mM ammonium acetate buffer
pH 5.0 and extracted with a flow ranging from 0.1 to 7 ml/
min. Paclitaxel concentration in the eluates were deter-
mined by scintillation counting.
Recovery studies of each step in the extraction process
were not performed with docetaxel, as radiolabelled
docetaxel was not available. For this compound, the total
recovery was used to evaluate the effects of the modifica-
tions made to the extraction method.
Linearity, accuracy and precision
For paclitaxel, the linearity was determined by analysing
calibration standards in duplicate at five levels (1000,
100, 10, 1.2 and 0.7 nM), and for docetaxel at eight levels
(1000, 500, 250, 100, 25, 10, 2.5 and 1 nM) using single
samples. The validation for both compounds included
five calibrator curves analysed over a period of 8–10 days.
Three quality control (QC) samples at each level were pre-
pared separately and used for determining accuracy and
precision for the paclitaxel method. In the analysis of
docetaxel, QC samples in triplicate at three levels (750, 50
and 5 nM) were included in each run and used for deter-
mination of accuracy and precision. Additional samples
(5 at each level) containing 1 nM and 2 nM of docetaxel
were included to verify the limit of quantitation. All cali-
brator curves were calculated using weighted least squares
regression (WLS) using a weighing factor of 1/x, where x is
the analyte concentration.
Influence of Cremophor EL on assay performance
Eighteen samples of 4 ml EDTA-plasma containing 0.5%
Cremophor EL and eighteen samples containing 1% Cre-
mophor EL were prepared. Nine samples with Cremophor
EL-free plasma served as controls. All samples contained
50 nM of paclitaxel with 14C-paclitaxel as tracer. Lipase
was added to an enzyme concentration of 125 U/ml
plasma to 9 samples in each group. The samples were
incubated at 37°C for 30 min to enzymatically degrade
the Cremophor EL. The Cremophor EL concentrations
were determined after 0, 2, 5, 10, 15 and 30 minutes ofBMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
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incubation. Subsequent to enzyme treatment, the samples
from the 1%-group were extracted in triplicate on three
different batches of SPE-columns together with the Cre-
mophor EL-free samples. Paclitaxel concentrations in the
eluates were determined by scintillation counting.
Patients
Blood samples were obtained from 10 patients receiving
175 mg/m2 of paclitaxel as a 3 hours infusion as a part of
the treatment for advanced ovarian carcinoma. The sam-
ples were collected in EDTA tubes prior to the infusion,
and at 2 hours, 24 hours and 48 hours after the end of the
infusion. Plasma was frozen at -70°C until analysis. All
patients gave written informed consent.
In the docetaxel study, blood samples were obtained from
5 patients. One patient receiving 20 mg/m2 of docetaxel
and four patients receiving 100 mg/m2 of docetaxel as a 1-
hour infusion as a part of the treatment for non-small cell
lung cancer. The samples were collected in EDTA tubes
prior to the infusion, and at 1 hour, 2 hours and 24 hours
after the end of the infusion. Samples were collected from
two consecutive treatments in each patient. Plasma was
frozen at -70°C until analysis. All patients were enrolled
in clinical trials approved by the Regional Committee for
Medical Research Ethics and the Hospital Review Board.
The studies were performed in compliance with the World
Medical Association Declaration of Helsinki. Written
informed consent was obtained from all patients.
Results and discussion
Solid Phase Extraction, recovery studies
Recovery studies with paclitaxel using high sample vol-
umes (10 ml of diluted plasma) by the method of Willey
et al. [12] showed that losses during loading were 2% for
the first 4 ml of sample, 2.5% for the next 3 ml, and 4%
for the final 3 ml. A loss of 1% was observed in the first
wash with 2 ml acetate buffer. Another 3% was lost in the
second wash with 2 ml 20% methanol in acetate buffer.
Only 0.2% was lost during the wash with hexane. An aver-
age of 86% of the loaded radioactivity was recovered in
the eluate.
Increasing the flow during the extraction from 0.1 to 7 ml/
min had a strong negative effect on recovery (figure 2a).
Similarly, Rosing [24] found that 0.4 ml/min was optimal
in their automated docetaxel extraction. Obtaining a low
(<1 ml/min) and reproducible flow rate is difficult using
vacuum. Therefore all subsequent experiments were per-
formed by gravity (no vacuum) during conditioning,
loading of sample, and the first two washes. Extracting by
gravity also enabled one person to process many samples
in parallel as the columns do not dry out, the flow will
stop as the liquid reaches the top frit.
After determining the optimal conditions for loading of
large sample volumes, the next step was to improve the
washings to obtain clean extracts from large samples. The
volume of the first wash was increased from 2 ml to 10 ml,
the volume of the second wash was reduced from 2 ml to
1 ml as recommended by Huizing et al. [11], and the vol-
ume of the hexane-wash was increased to 5 ml.
Even with these modifications we still observed a number
of background/endogenous peaks in the chromatogram,
Influence of sample flow and sample volume on paclitaxel  recovery Figure 2
Influence of sample flow and sample volume on pacli-
taxel recovery. 
2a: Influence of the flow during the extraction on 
paclitaxel recovery. A total of 18 samples of 4 ml EDTA-
plasma containing 14C-paclitaxel as tracer were extracted 
with a flow ranging from 0.1 to 7 ml/min in 3 separate exper-
iments (experiment 1: ● , 2: ▼  and 3: ■ ). 
2b: Relationship between sample size and response. 
Using a sample size of 0.5, 1, 2, 3 and 4 ml of plasma with a 
flow of <0.5 ml/min during the extraction caused a linear 
increase in detector response with increasing sample size. 
Data from 3 separate experiments with a total number of 25 
determinations are included in figure 2b. The data points 
given are mean values with error bars representing ± 1SD.BMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
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and when extracting from large sample volumes particles
in the reconstituted samples. As some of the interfering
peaks were present also in reagent blanks, i.e. samples
without plasma, all reagents were checked separately and
we found that several of the peaks originated from the elu-
tion of samples into polypropylene tubes.
A screening of solvents suitable for eluting paclitaxel
showed that non-water miscible organic solvents gave the
cleanest extracts. Ethyl acetate eluted 89 ± 2% (mean ±
1SD) of paclitaxel in the first 250 µl, 3 ± 1% in the second
and 0.3 ± 0.1% in the third aliquot of 250 µl. Using only
2 aliquots of 250 µl of ethyl acetate, a near quantitative
elution was obtained. The low volume of solvent enabled
elution directly into 1.1 ml glass injection vials, and the
solvent was completely evaporated within 60 minutes in
a vacuum centrifuge. Reconstitution in 40% acetonitrile
gave particle-free samples that could be injected without
prior centrifugation. Losses due to sample transfer were
thereby minimized. With these modifications, and using
3H-paclitaxel as internal standard, samples of 0.5, 1, 2, 3
and 4 ml of plasma were extracted, and gave a linear
increase in response with increasing sample size (figure
2b).
Attempts to use the paclitaxel extraction method also for
docetaxel were unsuccessful due to low and variable
recovery. Rosing et al. [24] showed that end-capped cyano
columns were more suitable for the extraction of
docetaxel from plasma. This method however, did not
have sufficient sensitivity for undertaking pharmacoki-
netic determinations during low-dose therapy. Using the
experiences learned from the development of the method
for paclitaxel, we performed similar modifications to Ros-
ings method attempting to obtain a lower limit of detec-
tion. The sample volume was increased to 2 ml, and the
washings and elution was modified (table 1). Plastic tubes
were used for storing plasma samples, but not for rea-
gents, standards in acetonitrile or eluates in ethyl acetate.
Chromatography
We used columns with 3 µm particles instead of 5 µm par-
ticles for both methods. The smaller particles provide a
higher number of theoretical plates, and thereby sharper
chromatographic peaks and a better signal to noise ratio.
This may lower the limit of detection as reproducible peak
integration is facilitated.
The mobile phase used in the original method (acetate-
buffer/MeCN/MeOH) was found to have a substantial
absorbance at 227 nm, and a long equilibration was nec-
essary to obtain a stable baseline. To lower the absorb-
ance, methanol was omitted in the mobile phase and
acetonitrile was used to adjust retention. The taxanes used
in this method did not have any ionizable groups in the
pH-range used for HPLC. The acetate buffer in the mobile
phase could be substituted for a 20 mM potassium phos-
Influence of Cremophor EL on extraction performance Figure 4
Influence of Cremophor EL on extraction perform-
ance. Recovery of paclitaxel from plasma samples containing 
1% Cremophor EL before ( ) and after ( ) lipase treatment, 
compared to plasma samples without Cremophor EL ( ). 
Three different batches of extraction columns were tested. 
The bars shown are mean values with error bars represent-
ing ± 1SD.
Degradation of Cremophor EL with lipase Figure 3
Degradation of Cremophor EL with lipase. Samples of 
EDTA-plasma containing 0.5% and 1% Cremophor EL were 
incubated at 37°C with 125 units of lipase/ml plasma. The 
data points given are mean values with error bars represent-
ing ± 1SD.BMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
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phate buffer pH 3.0 without affecting retention and with
a favorable effect on mobile phase absorbance.
Quantifying docetaxel in plasma by UV-detection is a
challenging task as docetaxel has a lower absorbance than
paclitaxel and is used in lower doses. To increase the sig-
nal height, and thereby the sensitivity, the 4.6 mm ID col-
umn used in the paclitaxel method was replaced by a 3
mm ID column in the docetaxel method. The nominal
increase in signal height is 2.4 times when the ID of the
column is reduced from 4.6 to 3 mm. The acetonitrile
content of the mobile phase and the temperature were
adjusted to optimize the separation between docetaxel
and the internal standard.
Paclitaxel of natural origin could not be used as internal
standard due to impurities interfering with the docetaxel
peak. Another candidate used by others, 2-methyl-paclit-
axel, also contained impurities and was excluded due to
late eluters. Semisynthetic paclitaxel (Sigma T 7191) had
sufficient purity to be suitable as an internal standard for
the docetaxel method.
Influence of Cremophor EL on assay performance
The experiments showed that Cremophor EL in plasma
could be rapidly degraded by incubation with lipase. After
10 minutes of incubation the concentration of Cremo-
phor EL was near the limit of detection for the method
(figure 3). Solid phase extraction of the samples from the
1%-group confirmed the results of Huizing et al. [11]
regarding the negative effect of Cremophor EL on the per-
formance of the extraction method, but also revealed that
lipase treatment of the samples diminish the negative
effect (figure 4).
Analytical performance
Because of the wide concentration range of the calibrator
curves for both paclitaxel and docetaxel, using WLS regres-
sion instead of classical linear regression is recommended
to prevent minor errors in the high end of the calibrator
curves resulting in major errors in the quantification of
samples in the low end of the calibrator curves [25,26].
Chromatograms of plasma samples containing docetaxel Figure 6
Chromatograms of plasma samples containing 
docetaxel. Chromatograms of blank plasma ( ), a calibra-
tion sample containing 5 nM of docetaxel ( ) and a patient 
sample containing 8.5 nM of docetaxel ( ). The docetaxel 
peak is marked by an asterisk ( ). The internal standard peak 
is marked ( ).
-
-
-
*
IS
Table 2: Intra- and inter-assay accuracy and precision (CV%) for paclitaxel and docetaxel determinations in plasma.
Concentration 
[nM]
Intra-assay variability Inter-assay variability
n Accuracy (%) CV (%) n Accuracy (%) CV (%)
Paclitaxel 1000 3 89 2 5 100 2
1 0 031 0 36 51 0 33
10 3 111 2 5 104 9
1.2 3 104 8 5 108 14
0.7 3 105 20 ND
Docetaxel 750 3 100 1 5 101 3
5 039 71 59 46
53 9 9 45 1 0 0 5
25 9 3 4 N D
15 9 6 1 2 N D
ND = Not done.BMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
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Paclitaxel
Using a sample size of four milliliters of plasma, the rela-
tionship between the drug concentration and the area
ratio was linear from 1.2 to 1000 nM paclitaxel in plasma.
The lowest level tested, 0.7 nM, was not included in the
calibrator curves due to deviation from linearity. WLS
regression of five calibrator curves in duplicate gave the
linear equation: Amount = 0.148(± 0.002) × Ratio –
0.149(± 0.2), r2 ranged between 0.998 and 1.000.
Inter- and intra-assay accuracy and precision are presented
in table 2. Based on these results the limit of quantitation
was set at 1.2 nM of paclitaxel. Recovery ranged between
76 and 104% for the QC samples.
Docetaxel
For the docetaxel assay, we used a sample size of two mil-
liliters of undiluted plasma. The method was linear over
the range tested, from 1 nM to 1000 nM docetaxel in
plasma. WLS regression of five calibrator curves with cali-
bration standards at eight levels gave the linear equation:
Amount = 277(± 6) × Ratio – 0.6(± 0.3), r2  ranged
between 0.999 and 1.000.
QC samples were run at three levels, 750 nM, 50 nM and
5 nM docetaxel in plasma. Inter- and intra-assay accuracy
and precision are presented in table 2. Recovery for the
standards from 1000 nM to 2.5 nM was 92 ± 5%, for the
1 nM level the recovery was 118 ± 11%. Based on these
results, the limit of quantitation was set at 1 nM of
docetaxel. Results from the additional samples containing
1 nM and 2 nM of docetaxel, included to verify the limit
of quantitation, may be found in table 2.
Patients
Paclitaxel
Chromatograms from the analysis of patient samples and
standards are shown in figure 5. At 2, 24, and 48 hours
after the end of infusion, the paclitaxel plasma concentra-
tions were 860 ± 240 nM, 57 ± 16 nM and 21 ± 7 nM
respectively.
Docetaxel
Chromatograms from the analysis of patient samples and
standards are shown in figure 6. At 1, 2, and 24 hours after
the end of infusion, the docetaxel concentration in the
high-dose patients were 370 ± 140 nM, 170 ± 50 nM and
23 ± 3 nM respectively, and 100 nM, 60 nM and 8.1 nM
in the low-dose patient. Seeing that the limit of quantita-
tion was as low as 1 nM of docetaxel, it was decided to
increase the sampling period in the clinical study to 72
hours to get a more complete picture of the elimination of
docetaxel. Median docetaxel concentration at 72 hours in
the low-dose patients included so far was 2.8 nM.
Stability
Stability of paclitaxel and docetaxel has been studied
extensively by others. Paclitaxel appeared to be stable in
frozen (-20°C) human plasma for up to two years, and up
to three freeze-thaw cycles did not affect recovery. Refrig-
erated at +4°C, paclitaxel was stable for at least 24 hours
in human plasma. At room temperature however, storage
should be limited to 4–8 hours [12,17]. Samples reconsti-
tuted in 40% MeCN were stable for at least 24 hours [27].
Similar results have been found regarding stability of
docetaxel [4,19,24]
Conclusion
We have developed an HPLC method using UV detection
capable of quantifying 1 nM of docetaxel in plasma sam-
Chromatograms of plasma samples containing paclitaxel Figure 5
Chromatograms of plasma samples containing paclit-
axel. 5a: Chromatogram from a patient sample taken 2 
hours after the infusion of 175 mg of paclitaxel/m2 to a 
patient. The paclitaxel peak is marked by an asterisk ( ). The 
signal is attenuated by a factor of 5 from nine minutes to get 
all peaks on scale. 5b: Chromatograms of a calibration sample 
containing 1.2 nM of paclitaxel ( ) and a plasma blank ( ). 
The paclitaxel peak is marked by an asterisk ( ).
*
- -
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ples, which is sufficient sensitivity to undertake determi-
nations up to 72 hours after an infusion of 20 mg/m2 of
docetaxel. Cancer cell lines tested in vitro gave IC50-values
for docetaxel ranging from 5 to 40 nM [2]. Using this
range as a guideline for which blood concentrations of
docetaxel may be considered as pharmacologically active,
the method presented here should be useful for pharma-
cokinetic determinations at all relevant doses of
docetaxel.
Using a similar methodology paclitaxel can be quantified
down to a concentration of 1.2 nM in plasma with accept-
able accuracy and precision. If we were to use the paclit-
axel method in large series of samples however, we would
consider testing out two modifications: first finding a
more convenient internal standard than 3H-paclitaxel,
and second to reduce the sample size to 2 ml plasma and
maintaining the sensitivity by reducing the column inter-
nal diameter to 3 mm.
Chromatographic methods based on UV detection will
inevitable involve a more complex sample preparation
than methods based on MS detection. This should how-
ever be weighted against the costs of purchasing and run-
ning LC-MS systems.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
AA was the main designer, performed the laboratory work
presented in this paper and drafted the manuscript. DJW
and HO participated in designing the study, and in man-
uscript preparation. PFB and SAa participated in designing
the study and in the selection of patients. GBK partici-
pated in the selection of patients. All authors read and
approved the final manuscript.
Acknowledgements
The assistance of the study nurses Grethe Lauvvang and Kristin Øwre from 
Department of Clinical Research, and Torill Berg from Department of 
Gynecologic Oncology is highly appreciated and acknowledged.
References
1. Sonnichsen DS, Relling MV: Clinical pharmacokinetics of paclit-
axel.  Clin Pharmacokinet 1994, 27:256-269.
2. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel.
Clin Pharmacokinet 1999, 36:99-114.
3. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH: Preclinical
pharmacokinetics of paclitaxel and docetaxel.  Anticancer Drugs
1998, 9:1-17.
4. Baker SD, Zhao M, He P, Carducci MA, Verweij J, Sparreboom A:
Simultaneous analysis of docetaxel and the formulation vehi-
cle polysorbate 80 in human plasma by liquid chromatogra-
phy/tandem mass spectrometry.  Analytical Biochemistry 2004,
324:276-284.
5. van Tellingen O, Beijnen JH, Verweij J, Scherrenburg EJ, Nooijen WJ,
Sparreboom A: Rapid esterase-sensitive breakdown of polys-
orbate 80 and its impact on the plasma pharmacokinetics of
docetaxel and metabolites in mice.  Clin Cancer Res 1999,
5:2918-2924.
6. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Wool-
lett AM, Morton CG, Bishop JF: Cremophor pharmacokinetics in
patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
J Natl Cancer Inst 1996, 88:1297-1301.
7. Meerum TJ, van Tellingen O, Nannan PV, Huizing MT, Schellens JH,
Ten Bokkel Huinink WW, Boschma MU, Giaccone G, Veenhof CH,
Beijnen JH: Cremophor EL pharmacokinetics in a phase I
study of paclitaxel (Taxol) and carboplatin in non-small cell
lung cancer patients.  Anticancer Drugs 2000, 11:687-694.
8. Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter
G, Sparreboom A: Linearized colorimetric assay for cremo-
phor EL: application to pharmacokinetics after 1-hour pacli-
taxel infusions.  Anal Biochem 1998, 261:198-202.
9. van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Spar-
reboom A: Inter-relationships of paclitaxel disposition, infu-
sion duration and cremophor EL kinetics in cancer patients.
Anticancer Drugs 2000, 11:331-337.
10. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ,
Beijnen JH: Cremophor EL causes (pseudo-) non-linear phar-
macokinetics of paclitaxel in patients.  Br J Cancer 1999,
81:330-335.
11. Huizing MT, Rosing H, Koopmans FP, Beijnen JH: Influence of Cre-
mophor EL on the quantification of paclitaxel in plasma
using high-performance liquid chromatography with solid-
phase extraction as sample pretreatment.  J Chromatogr B
Biomed Sci Appl 1998, 709:161-165.
12. Willey TA, Bekos EJ, Gaver RC, Duncan GF, Tay LK, Beijnen JH, Far-
men RH: High-performance liquid chromatographic proce-
dure for the quantitative determination of paclitaxel (Taxol)
in human plasma.  J Chromatogr 1993, 621:231-238.
13. Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J:
Determination of paclitaxel in human plasma using single
solvent extraction prior to isocratic reversed-phase high-
performance liquid chromatography with ultraviolet detec-
tion.  J Chromatogr B Biomed Sci Appl 1998, 705:159-164.
14. Loos WJ, Verweij J, Nooter K, Stoter G, Sparreboom A: Sensitive
determination of docetaxel in human plasma by liquid-liquid
extraction and reversed-phase high-performance liquid
chromatography.  J Chromatogr B Biomed Sci Appl 1997,
693:437-441.
15. Ciccolini J, Catalin J, Blachon MF, Durand A: Rapid high-perform-
ance liquid chromatographic determination of docetaxel
(Taxotere) in plasma using liquid-liquid extraction.  J Chroma-
togr B Biomed Sci Appl 2001, 759:299-306.
16. Parise RA, Ramanathan RK, Zamboni WC, Egorin MJ: Sensitive liq-
uid chromatography-mass spectrometry assay for quantita-
tion of docetaxel and paclitaxel in human plasma.  Journal of
Chromatography B 2003, 783:231-236.
17. Alexander MS, Kiser MM, Culley T, Kern JR, Dolan JW, McChesney
JD, Zygmunt J, Bannister SJ: Measurement of paclitaxel in biolog-
ical matrices: high-throughput liquid chromatographic-tan-
dem mass spectrometric quantification of paclitaxel and
metabolites in human and dog plasma.  J Chromatogr B Analyt
Technol Biomed Life Sci 2003, 785:253-261.
18. Wang LZ, Goh BC, Grigg ME, Lee SC, Khoo YM, Lee HS: A rapid
and sensitive liquid chromatography/tandem mass spec-
trometry method for determination of docetaxel in human
plasma.  Rapid Commun Mass Spectrom 2003, 17:1548-1552.
19. Grozav AG, Hutson TE, Zhou X, Bukowski RM, Ganapathi R, Xu Y:
Rapid analysis of docetaxel in human plasma by tandem
mass spectrometry with on-line sample extraction.  Journal of
Pharmaceutical and Biomedical Analysis 2004, 36:125-131.
20. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson
AS, Eckhardt SG: Analysis of docetaxel pharmacokinetics in
humans with the inclusion of later sampling time-points
afforded by the use of a sensitive tandem LCMS assay.  Cancer
Chemother Pharmacol 2003, 52:159-166.
21. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, Wolff
AC, Sparreboom A, Carducci MA: Comparative Pharmacokinet-
ics of Weekly and Every-Three-Weeks Docetaxel.  Clin Cancer
Res 2004, 10:1976-1983.
22. Sparreboom A, Loos WJ, Verweij J, de Vos AI, van der Burg ME,
Stoter G, Nooter K: Quantitation of Cremophor EL in humanPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Clinical Pharmacology 2006, 6:2 http://www.biomedcentral.com/1472-6904/6/2
Page 10 of 10
(page number not for citation purposes)
plasma samples using a colorimetric dye-binding micro-
assay.  Anal Biochem 1998, 255:171-175.
23. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff
T, Viswanathan CT, Cook CE, McDowall RD: Analytical methods
validation: bioavailability, bioequivalence and pharmacoki-
netic studies. Conference report.  J Pharm Sci 1992, 81:309-312.
24. Rosing H, Lustig V, Koopman FP, ten Bokkel H, Beijnen JH: Bio-anal-
ysis of docetaxel and hydroxylated metabolites in human
plasma by high-performance liquid chromatography and
automated solid-phase extraction.  J Chromatogr B Biomed Sci
Appl 1997, 696:89-98.
25. Almeida AM, Castel-Branco MM, Falcao AC: Linear regression for
calibration lines revisited: weighting schemes for bioanalyti-
cal methods.  Journal of Chromatography B 2002, 774:215-222.
26. Nagaraja NV, Paliwal JK, Gupta RC: Choosing the calibration
model in assay validation.  J Pharm Biomed Anal 1999, 20:433-438.
27. Song D, Au JL: Isocratic high-performance liquid chromato-
graphic assay of taxol in biological fluids and tissues using
automated column switching.  J Chromatogr B Biomed Appl 1995,
663:337-344.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6904/6/2/prepub